[Re-posted from Knowledge Ecology International.] By James Love, Director of Knowledge Ecology International (KEI) – 22 May 2019 Perhaps the toughest issue in the 72nd World Health Assembly negotiations on a WHO transparency resolution concerns the proposal to require public reporting of the costs of each clinical trial undertaken for development of drugs, vaccines, cell- […] Continue reading ->
Thomas Cueni, director general of the International Federation of Pharmaceutical Manufacturers and Associations, shared his view on fair pricing with Health Policy Watch: “Most of us can probably agree that innovation is meaningless if it does not reach patients. At the same time, a Fair Price must strike a balance between a price that is […] Continue reading ->
A human embryo’s DNA is “edited” to take out a disease. Surgeons practice complicated procedures on models created by 3-D printers. A pre-programmed drone collects blood samples from residents of a rural village and travels back to the capital. These awe-inspiring scenarios have all recently unfolded in what is undoubtedly a golden era of innovation in healthcare. Continue reading ->
Surely, the topic of human mobility has been the stumbling block in the common agenda of European countries for the last few years. In fact, the very existence of the European Union as we have known it so far is at stake, on this political issue. A certain degree of prudence would seem understandable, then, a few months ahead of the May EU elections. Surely, the intergovernmental nature of the UN agencies force them to interact with Member States, that is why exacerbating the political arena is a risky operation that may not pay off at all, in the long run. Moreover, for WHO Europe, the report on the health of refugees and migrant people in the 53 countries of the region is the first one of its kind, which may explain the hesitance of the beginner. But it is difficult to deny a bitter aftertaste, especially after the press conference. Continue reading ->